Abstract:Background: Chemotherapy is currently one of the most common/important treatments for cancers; however the occurrence of multidrug resistance (MDR) impedes the successful application of chemotherapeutic agents. The active efflux of anti-cancer drugs through multi-drug resistance protein 1 (MRP1) remains the dominant mechanism of MDR. However, mechanisms underlying the MRP1 upregulation during tumorigenesis and chemotherapy remain elusive. Methods: MRP1 expression, the efflux probability and viability were measured to evaluate MDR of human lung cancer A549/DDP and H1299 cells. Pharmacological treatment, shRNA-based konckdown and rescue were used to assess the function of JNK (c-Jun N-terminal kinase) and Sp1 (stimulatory phosphatase 1). Chromatin immunoprecipitation and dual-luciferase reporter assay were used to test the direct binding and activation of MRP1 promotor by Sp1. Findings: Pharmacological analysis and JNK knockdown revealed the direct modulation of MRP1 expression and MDR by by the JNK signaling pathway. Furthermore, the transcript factor Sp1 downstream of JNK showed close association with MRP1 expression and MDR. Chromatin immunoprecipitation and luciferase assays revealed the direct binding and activation of MRP1 promoter by Sp1, while Sp1 knockdown decreased MRP1 expression and reversed MDR. Importantly, the MRP1 upregulation and MDR mediated by JNK activation were substantially abolished by Sp1 knockdown in both A549/DDP and H1299 cells. Interpretation: This work demonstrates that Sp1 is a critical transcription factor for MRP1 downstream of JNK and plays a key role in MRP1 upregulation and MDR during tumorigenesis and chemotherapy. Targeting Sp1 expression/activation sheds new light on the clinical chemotherapy treatments of cancers.Funding Statement: This work was supported by the National Natural Science Foundation of China (31400708 and 31670843), the Natural Science Foundation of Heilongjiang Province, China (C200624, C201241, and C201453), the Shaanxi Natural Science Funds for Distinguished Young Scholars of China (2019JC-07), the Key Research and Development Program of Shaanxi Province, China (2017SF-113), and the Fundamental Research Funds for the Central Universities (2017qngz10).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Not required.

[Multidrug Resistant Gene MDR1 Contributes to Development of Imatinib-Resistance in Ph (+) Acute Lymphoblastic Leukemia Cell Line SUP-BS15RI].

Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

DEVELOPMENT OF A K562 MULTIDRUG-RESISTANT CELL LINE AND STUDY ON PROTEINS WITH ALTERED EXPRESSION

Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling

Reversal of Multidrug Resistance by Magnetic Fe3o4 Nanoparticle Copolymerizating Daunorubicin and Mdr1 Shrna Expression Vector in Leukemia Cells

Changes in the Expression of Mir-381 and Mir-495 Are Inversely Associated with the Expression of the MDR1 Gene and Development of Multi-Drug Resistance

SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

[Identification of Multidrug Resistance Related Genes in Leukemia by Suppression Subtractive Hybridization].

Reversal in Multidrug Resistance by Magnetic Nanoparticle of Fe3o4 Loaded with Adriamycin and Tetrandrine in K562/A02 Leukemic Cells

[Study on the Mechanisms of Imatinib-Resistance of Cancer Stem-Like Cells in K562/Vp16 Cell Line].

Expression of Multidrug Resistance Gene in Human Cancers

Knockdown of MRP4 by Lentivirus-Mediated Sirna Improves Sensitivity to Adriamycin in Adriamycin-Resistant Acute Myeloid Leukemia Cells

[Reversal of Multi-Drug Resistance in K562/A02 Cells by Small Interference RNA of Mdr1 Gene].

Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin

[The Reverse Effect on Drug-Resistance Against Tyrosine Kinase Inhibitor STI571 in Mdr1 and Bcr-Abl Positive Leukemic Cells].

Overcoming Multidrug-Resistance in Vitro and in Vivo Using the Novel P-glycoprotein Inhibitor 1416.

[Expression of MDR1 and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumor Cells].

Reversal of P-gp Mediated Multidrug Resistance In-Vitro and In-Vivo by FG020318

Functional Study of the Novel Multidrug Resistance Gene Ha117 and Its Comparison to Multidrug Resistance Gene 1

Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia